Lung Cancer
Volume 45, Supplement , Pages S93-S96, August 2004

Considerations for post-operative radiotherapy to the hemithorax following extrapleural pneumonectomy in malignant pleural mesothelioma

  • Suresh Senan

      Affiliations

    • Department of Radiation Oncology, Vu University Medical Center, De Boelelaan 1117, PO box 7057, 1007 MB Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31-20-444-0414; fax: +31-20-444-0410.
  • ,
  • Marjan van de Pol

      Affiliations

    • Department of Radiation Oncology, Erasmus MC—Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

Abstract 

With growing interest in evaluating extrapleural pneumonectomy (EPP) and post-operative in selected patients with early stage malignant pleural mesothelioma, it is essential that clinical trials should be conducted using a clear and reproducible radiotherapy protocol. The considerations which have determined the policy of radiotherapy planning and treatment delivery for patients with mesothelioma in The Netherlands are given. As well as general considerations such as patient selection, target volume and critical organ delineation, a dose-fractionation scheme, constraints relating to normal tissue, treatment planning, the type of external beam equipment, treatment verification and radiation toxicity and scoring are all taken into account.

Keywords:  Extrapleural pneumonectomy, Post-operative radiotherapy, Early stage malignant pleural mesothelioma, Clinical target volume, Intensity-modulated radiotherapy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0169-5002(04)00180-1

doi:10.1016/j.lungcan.2004.04.019

Lung Cancer
Volume 45, Supplement , Pages S93-S96, August 2004